Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Biogen Inc    BIIB


News SummaryMost relevantAll newsSector newsTweets 

Biogen Idec Inc. : Biogen 4th-Quarter Profit Falls 2.7% on Higher Costs; Revenue Up

share with twitter share with LinkedIn share with facebook
share via e-mail
01/28/2013 | 01:13pm CEST
   By Tess Stynes and Melodie Warner 

Biogen Idec Inc.'s (BIIB) fourth-quarter earnings fell 2.7% as the biotechnology company's efforts to bulk up its product pipeline masked its revenue growth.

The company also forecast 2013 adjusted earnings of $7.15 to $7.25 a share on about 10% revenue growth. Analysts surveyed by Thomson Reuters expect $7.27 a share on a 9% rise in revenue to $5.98 billion.

Biogen on Thursday said a new version of its blockbuster multiple-sclerosis drug Avonex was successful in a late-stage trial, strengthening the company's stable of drugs for the degenerative nerve disease. However, the overall market for such injectable drugs is expected to decline sharply amid a growing market for oral-pill-based drugs. Biogen's own BG-12 pill could be approved and launched in the U.S. as soon as March.

Biogen has been beefing up its sales force and readying its manufacturing supply chain as some drugs in its late-stage product pipeline have been drawing closer to entering the market.

Research and development costs rose 1.8% in the latest period while selling, general and administrative costs jumped 32%.

Biogen reported a profit of $292.1 million, or $1.23 a share, down from $300.2 million, or $1.22 a share, a year earlier. Excluding items such as stock-option expense, amortization and restructuring charges, per-share earnings fell to $1.40 from $1.51. Revenue increased 6.9% to $1.42 billion.

Analysts polled by Thomson Reuters most recently projected earnings of $1.46 a share on revenue of $1.39 billion.

In the latest quarter, sales of Avonex rose 7.1% to $753.2 million.

Shares closed Friday at $146.20 and were inactive premarket. The stock is up 23% over the past year.

Write to Tess Stynes at [email protected] and Melodie Warner at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BIOGEN INC
05/24 BIOGEN : ’s FAMPYRA® Granted Standard Marketing Authorization in European ..
05/18 BIOGEN : Acquires Remedy Pharmaceuticals’ Late-Stage Drug CIRARA™
05/17 BIOGEN : to Present at the Bernstein 33rd Annual Strategic Decisions Conference
05/15 BIOGEN : Acquires Remedy Pharmaceuticals’ CIRARA™ for Large Hemisphe..
04/25DJNasdaq Composite Tops 6000 for First Time
04/25 BIOGEN : Reports First Quarter 2017 Revenues of $2.8 Billion
04/24 BIOGEN : TECFIDERA® and TYSABRI® Data Demonstrate Improved Outcomes with Early M..
04/21 BIOGEN : SPINRAZA® (nusinersen) Receives Positive CHMP Opinion for the Treatment..
04/18 BIOGEN : Highlights Advances from Its Neurology Research Programs and Portfolio ..
03/28 BIOGEN : to Present Data at the 13th International Conference on Alzheimer&rsquo..
More news
Sector news : Biopharmaceuticals
05/26DJSUN PHARMACEUTICAL INDUSTRIES : Pharma 4Q Profit Falls 13.6%
05/24 JOHNSON & JOHNSON : J&J settles drug manufacturing probe by U.S. states for $33 ..
05/24 FTSE edges up helped by M&S, but miners weigh
05/23DJMERCK : FDA OKs Merck's Keytruda to Treat Cancers With Genetic Defects -- Update
05/23DJMERCK : FDA Approves Merck's Keytruda to Treat Cancers With Genetic Defects
More sector news : Biopharmaceuticals
News from SeekingAlpha
05/26 Time For Tau - For Now
05/26 STOCK EXCHANGE : Time to reconsider health care?
05/25 FDA drug approvals rebound from last year, up over 100% yoy
05/24 Roche investigating brain infection in Ocrevus patient
05/24 BBP : A Diversified Biotech ETF
Financials ($)
Sales 2017 11 387 M
EBIT 2017 5 829 M
Net income 2017 3 655 M
Finance 2017 296 M
Yield 2017 -
P/E ratio 2017 14,95
P/E ratio 2018 11,97
EV / Sales 2017 4,65x
EV / Sales 2018 4,20x
Capitalization 53 198 M
More Financials
Duration : Period :
Biogen Inc Technical Analysis Chart | BIIB | US09062X1037 | 4-Traders
Full-screen chart
Technical analysis trends BIOGEN INC
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 318 $
Spread / Average Target 27%
Consensus details
EPS Revisions
More Estimates Revisions
Michel Vounatsos Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Paul J. Clancy Chief Financial Officer & Executive Vice President
Alfred W. Sandrock Chief Medical Officer & Executive Vice President
Spyridon Artavanis-Tsakonas Chief Scientific Officer & Executive VP
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BIOGEN INC-4.03%53 198
CSL LIMITED31.55%44 709
GRIFOLS SA31.81%17 451
More Results